EUCTR2017-004220-30-PL进行中（未招募）1 期
A Randomized, Double blind, Placebo controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide SC for the Treatment of Men with Osteoporosis.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. The subject is a healthy ambulatory male from 40 to 85 years of age (inclusive) with primary osteoporosis or osteoporosis associated with hypogonadism.
- •2. The subject has a bone mineral density (BMD) T-score (based on the male reference range as assessed by the central imaging vendor) of
- •a. = –2.5 at the lumbar spine (L1–L4) or hip (femoral neck or total hip) by DXA or
- •b. <–1.5 and with radiologic evidence of vertebral fracture or a documented (radiograph films or report) history of low-trauma nonvertebral fracture sustained in the past 5 years.
- •c. Men older than 65 years may be enrolled if they have a BMD T-score = –2.0 even if they do not meet the fracture criteria.
- •3. The subject is in good general health as determined by medical history and physical examination (including vital signs), has a body mass index (BMI) of 18.5 to 33, inclusive, and is without evidence of a clinically significant abnormality in the opinion of the Investigator, or none for which there is a reasonable chance of interfering with the subject’s health and/or medical treatment during the study. The subject has a body mass index (BMI) of 18.5 to 33, inclusive. The body mass index is derived from the subject's height and weight. In the case where a subject's height cannot be adequately assessed (e.g., due to vertebral compression fractures or scoliosis), the subject's historical height (as documented in the subject's medical record) will be used to derive the BMI.
- •4. Hypogonadal subjects whose doses of androgens have been stable for at least twelve months before randomization are eligible and may continue therapy during the study.
- •5. The subject has serum calcium (albumin-corrected), PTH, serum phosphorus and alkaline phosphatase, and thyroid stimulating hormone (TSH) values all within the normal range during the Screening Period. Any subject with an elevated alkaline
- •phosphatase value and who meets all other entry criteria must have a normal bone-specific alkaline phosphatase to be enrolled. Any subject with a TSH value outside of the normal range must have central laboratory reported T3 and free T4 values within the normal ranges to be enrolled.
- •6. The subject has serum 25-hydroxyvitamin D values = 20 ng/mL and within 3 times the upper normal range. Subjects with serum 25-hydroxyvitamin D levels < 20 ng/ml may be treated with vitamin D and re-tested once during the Screening Period.
- •7. The subject’s systolic blood pressure is = 100 and = 155 mmHg, diastolic blood pressure is = 40 and = 95 mmHg, and heart rate is = 45 and = 100 bpm (taken sitting or supine). Any recorded values outside of these ranges and assessed by the Investigator to be not clinically significant must be reviewed with the Sponsor Medical Monitor for approval prior to enrollment.
- •8. The subject has no clinically significant abnormality of serum hemoglobin, hematocrit, WBC and platelets, or usual serum biochemistry: electrolytes, renal function, liver function and serum proteins that might be expected to interfere with the subject’s health and/or medical treatment during the study.
- •9. In subjects who have partners of childbearing potential, the subject and his partner should abstain from sexual intercourse, or use highly effective contraceptive measures (e.g. oral contraceptive and condom, intrauterine device (IUD) and condom, or diaphragm with spermicide and condoms; other forms of contraception must be approved by the medical monitor) when
排除标准
- •General exclusion criteria
- •1. Presence of abnormalities of the lumbar spine that would prohibit assessment of spinal bone mineral density, defined as having at least 2 radiologically evaluable vertebrae within L1–L4 as assessed by the central imaging vendor.
- •Anatomically abnormal vertebrae are excluded if:
- •o They are clearly abnormal and non-assessable within the resolution of the system
- •o There is a more than 1.0 T-score difference between the vertebra in question and adjacent vertebrae.
- •2. A BMD T-score of = –3.5 at the total hip, femoral neck, or lumbar spine based upon the male reference range.
- •3. Unevaluable hip BMD or subjects who have undergone bilateral hip replacement (unilateral hip replacement is acceptable).
- •4. Fragility fracture within the prior twelve months.
- •5. History of severe vertebral fracture or > 2 moderate vertebral fractures.
- •6. History of bone disorders (e.g., Paget’s disease) other than osteoporosis.
- •7. Subjects with clinical signs of hypogonadism present at screening who plan to initiate testosterone replacement.
- •8. History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine.
- •9. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances to a degree that would interfere with the interpretation of study data or compromise the safety of the subject.
- •10. History of Cushing’s disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year.
- •11. History of significantly impaired renal function (serum creatinine >177 µmol/L or >2.0 mg/dL. If the serum creatinine is > 1.5 and = 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be = 37 mL/min.
- •12. History of any cancer within the past 5 years (other than basal cell or squamous cancer of the skin).
- •13. History of osteosarcoma at any time.
- •14. Subjects with hereditary disorders predisposing them to osteosarcoma.
- •15. History of nephrolithiasis or urolithiasis within the past five years.
- •16. Subjects known to be positive for Hepatitis B, Hepatitis C, HIV-1 or HIV-2. Testing is not required in the absence of clinical signs and symptoms suggestive of HIV infection or acute or chronic hepatitis.
- •Medication-related exclusion criteria:
- •17. Known history of hypersensitivity to any of the test materials or related compounds.
- •18. Prior treatment with PTH- or PTHrP-derived drugs, including abaloparatide or teriparatide, or PTH(1-84).
- •19. Prior treatment with IV bisphosphonates at any time or oral bisphosphonates within the past three years. Subjects who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment.
- •20. Treatment with fluoride or strontium in the past five years or prior treatment with gallium nitrate, or other bone-acting investigational agents at any time. Limited use of gallium citrate/nitrate for diagnostic purposes (i.e., a gallium scan) is not exclusionary.
- •21. Prior treatment with calcitonin or tibolone in the past 6 months.
- •22. Prior treatment with denosumab in the past 18 months.
- •23. Treatment with anticonvulsants that affect vitamin D metabolism (phenobarbital, phenytoin, carba
研究者
相似试验
已完成
2 期
A Clinical Study to evaluate the Efficacy and Safety of TLPL/AY/04/2008 as an adjuvant to Oral Hypoglycemic agents (OHAs) in Type 2 Diabetic Patients.CTRI/2009/091/000605Tulip Lab Pvt Ltd80
已完成
2 期
A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense Inhibitor of Prekallikrein, in Patients with Hereditary AngioedemaHereditary angioedemaNL-OMON49723Ionis Pharmaceuticals, Inc.8
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic AdenocarcinomaEUCTR2007-004102-27-NLSciClone Pharmaceuticals, Inc.153
进行中（未招募）
1 期
This is a randomized, double-blind, Placebo controlled trial to evaluate the efficacy of ISIS 721744 in Patients with Hereditary AngioedemaMedDRA version: 20.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary AngioedemaEUCTR2019-001044-22-GBIonis Pharmaceuticals, Inc.24
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic AdenocarcinomaEUCTR2007-004102-27-HUSciClone Pharmaceuticals, Inc.153